Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Webcast ImageWebcast
Advanced Accelerator Applications Third Quarter 2016 Earnings Conference Call (Replay)
11/28/16 at 4:30 p.m. ET
Advanced Accelerator Applications Third Quarter 2016 Earnings Conference Call
Monday, November 28, 2016 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.... more >

Advanced Accelerator Applications Third Quarter 2016 Earnings Conference Call

November 28, 2016
4:30 p.m. ET

Click here for Webcast

Latest Newsmore >
11/28/16
Advanced Accelerator Applications Reports 15.4% Sales Growth in the Third Quarter of 2016 and Feedback from the FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
Conference Call Today at 4:30 p.m. ET Highlights: Sales for the third quarter of 2016 increased 15.4% compared to the third quarter of 2015 Closed $150 million follow-on public offering and subsequent underwriters option to purchase additional $22.5 million The U.S. Food and Drug Administration (FDA) issued feedback via a Discipline Review Letter on the New Drug Application (NDA) for Lutathera® for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) The Euro... 
11/23/16
Advanced Accelerator Applications to Announce Third Quarter and Nine-Month 2016 Financial Results on November 28
Conference Call at 4:30 p.m. ET SAINT-GENIS-POUILLY, France, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the company will report its financial results for the third quarter and nine-month period ended September 30, 2016, on November 28. Stefano Buono, Chief Executive Officer and Heinz Mäusli, Chief Financial Officer will host a conferenc... 
11/02/16
Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products
SAINT-GENIS-POUILLY, France, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, announced today that the company has been granted marketing authorization in Switzerland for two Positron Emission Tomography (PET) products, DOPAVIEW and AAACholine. DOPAVIEW is AAA’s brand name for 6-fluoro-(18F)-L-DOPA, a DOPA analogue. DOPA is an aromatic amino acid that accumulates rapidl... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources